SCIENCE NEWS Biomarker Panel Identifies Prostate Cancer with 90 Percent Accuracy Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. [Press release from the American Association for Cancer Research (AACR) discussing data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development] Jevtana(R) Improves Survival in Advanced Prostate Cancer Patients Sanofi-aventis announced that data from the Phase III TROPIC study, which was the basis for the U.S. Food and Drug Administration (FDA) approval of Jevtana® (cabazitaxel) Injection, was published. [Press release from Sanofi-aventis discussing online prepublication in The Lancet] Surgery Found Effective for Patients with Aggressive Prostate Cancer In one of the first studies to focus exclusively on the outcomes after treatment for patients with high-risk prostate cancer, researchers have found that surgery provides high survival rates. [Press release from Mayo Clinic Press Release discussing data presented at the North Central Section of the American Urological Association’s 84th Annual Meeting]
|
INDUSTRY NEWS OncoGenex Pharmaceuticals Announces Initiation of a Phase II Trial Evaluating OGX-427 Treatment in Men with Advanced Prostate Cancer OncoGenex Pharmaceuticals, Inc. announced the initiation of a randomized, controlled, investigator-sponsored Phase II trial of OGX-427 in men with metastatic prostate cancer. [OncoGenex Pharmaceuticals, Inc. Press Release] Nanobubbles Get a Boost Lapotko’s Plasmonic Nanobubble Lab, a joint American-Belarusian laboratory for fundamental and biomedical nanophotonics, has received an R01 grant worth more than $1 million over the next four years to continue developing a method to track down individual cancer cells and destroy them in a single process. [Rice University Press Release] Warburg Pincus Agrees to Invest Up to $35 Million in Protox Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, jointly announced that they have entered into an Investment Agreement. [Protox Therapeutics Inc. Press Release] Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting Dendreon Corporation announced PROVENGE(R) (sipuleucel-T) data presentations taking place at the 25th International Society for Biological Therapy of Cancer (iSBTc) annual meeting in Washington, D.C. [Dendreon Corporation Press Release] AstraZeneca’s Zibotentan Flunks Late-Stage Prostate Cancer Trial AstraZeneca has suffered a setback in its oncology drug development strategy. The pharma giant reported that the closely watched prostate cancer therapy zibotentan failed a late-stage trial. [FierceBiotech]
|
POLICY NEWS NIH Grants Will Advance Studies of the Form and Function of Proteins The National Institutes of Health has awarded 23 grants for structural biology research totaling up to $290 million over five years. [National Institutes of Health, United States] NCBI Launches the Database of Genomic Structural Variations The National Institutes of Health announced the launch of a new resource, called the Database of Genomic Structural Variation, or dbVar, to help scientists understand how differences in DNA contribute to human health and disease. [National Institutes of Health, United States] NIH Releases Biennial Report of the Director Dr. Francis S. Collins, M.D., Ph.D, director of the National Institutes of Health, announced the release of the Biennial Report of the Director, NIH, for fiscal years 2008 and 2009. The report provides an integrated portrait of NIH research activities, making it easy for Congress, advocates and patient groups and the general public to understand the many activities of the agency. [National Institutes of Health, United States] The NCI Cancer Immunotherapy Trials Network (CITN) Seeks Member Clinical Sites (NOT-CA-10-034) [National Institutes of Health, United States] Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44]) (PAR-10-286) [National Institutes of Health, United States] Office of Biotechnology Activities, Office of Science Policy, Office of the Director; Notice of Meeting (FR Doc. 2010-23947) [National Institutes of Health, United States] National Center for Research Resources; Notice of Closed Meeting (FR Doc. 2010-23852) [National Institutes of Health, United States] Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-23847) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-23849) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23860) [National Institutes of Health, United States]
|
EVENTS (Listed by Date) 35th European Society for Medical Oncology (ESMO) Congress October 8-12, 2010 Milan, Italy American Association for Cancer Research (AACR) Translational Cancer Research for Basic Scientists October 17-22, 2010 Boston, United States 6th Modern Drug Discovery & Development Summit (M3D) October 20-22, 2010 San Francisco, United States American Institute for Cancer Research (AICR) 2010 Annual Cancer Research Conference October 21-22, 2010 Washington, DC, United States MENA Oncology Conference October 22-23, 2010 Cairo, Egypt Frontiers in Tumour Progression October 24-27, 2010 Madrid, Spain Select Biosciences 3rd Annual Molecular Diagnostics World Congress October 28-29, 2010 San Diego, United States UAE Cancer Congress 2010 October 28-30, 2010 Dubai, United Arab Emirates 6th National Cancer Research Institute (NCRI) Conference November 7-10, 2010 Liverpool, United Kingdom 9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research November 7-10, 2010 Philadelphia, United States 22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics November 16-19, 2010 Berlin, Germany Cancer Pharmacogenetics: Personalizing Medicine November 22-24, 2010 Madrid, Spain The 10th Annual Meeting of the Society Of Urologic Oncology (SUO) – 10th Annual Winter Meeting December 3-5, 2010 Bethesda, United States 33rd Annual San Antonio Breast Cancer Symposium December 8-12, 2010 San Antonio, United States American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer March 3-6, 2011 Vancouver, Canada IMPaCT: Innovative Minds in Prostate Cancer Today 2011 March 9-12, 2011 Orlando, United States The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics March 16-19, 2011 Las Vegas, United States American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 April 2-6, 2011 Orlando, United States International Society for Stem Cell Research (ISSCR) 9th Annual Meeting June 15-18, 2011 Toronto, Canada American Association for Cancer Research (AACR) Cancer Research Imaging Camp June 19-24, 2011 St. Louis, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community. JOB OPPORTUNITIES Cell Therapy Technologist (Opexa Therapeutics) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost. Visit here to post your career opportunities.
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or Suggestions? Email info@connexoncreative.com with your feedback. |
|
|